• 🌎 Worldwide
    • πŸ‡ΊπŸ‡Έ U.S.
    • πŸ‡¨πŸ‡¦ Canada
    • πŸ‡¬πŸ‡§ United Kingdom
    • 🌏 Asia
    • 🌍 Europe
    • 🌎 Latin America
    • 🌏 Oceania and Australasia
The Daily Marijuana Observer
SUBSCRIBE
  • Home
  • Latest
  • Business
  • Investments
  • Law
  • People
  • Health
  • Databases
No Result
View All Result
The Daily Marijuana Observer
  • Home
  • Latest
  • Business
  • Investments
  • Law
  • People
  • Health
  • Databases
No Result
View All Result
The Daily Marijuana Observer
No Result
View All Result
Home Investments

FSD Pharma and SciCann Therapeutics Launch Clinical Research Program in Israel

D.M.O. Newswire by D.M.O. Newswire
August 16, 2018
in Investments, Israel, Marijuana Stocks, Press Releases
Emerald Health Therapeutics Enters Research Agreement with VivaCell Biotechnologies to Evaluate Proprietary Cannabis Products

Photo by Pixabay on Pexels.com

78
SHARES
ShareShare

Toronto, Aug. 16, 2018 β€” /D.M.O. Newswire/ – FSD Pharma Inc. (“FSD Pharma”) (CSE:HUGE) (OTC:FSDDF) (FRA:0K9), announced today the launch of a clinical research collaborative program in Israel, via its strategic R&D partner, SciCann Therapeutics Inc. (“SciCann”)

This comprehensive clinical research program will be executed through SciCann‘s strategic alliance and collaboration agreement with Mor Research Applications Ltd. (“Mor”) – the technology transfer office and commercial arm of Clalit Healthcare Services, Israel’s largest medical insurer and healthcare provider, which operates a network of 14 full scale hospitals throughout Israel, employs over 9,000 physicians and serves the healthcare needs of over 50% of Israel’s population.

As announced previously, FSD Pharma has secured the exclusive licensing rights for the manufacturing and distribution of SciCann’s line of proprietary, patent-pending, cannabinoid-based and indication-specific products in Canada.

Under the strategic alliance agreement with Mor, FSD Pharma and SciCann will execute a series of rigorous, randomized, placebo-controlled clinical studies to demonstrate the safety and efficacy of these products, in order to bring to market advanced and innovative cannabinoid-based products that are backed up by solid clinical data achieved through the highest standards of rigorous and objective clinical research typical for the development process of pharmaceutical products.

Zeeshan Saeed, EVP and Director of FSD Pharma, stated “the launch of this clinical study collaboration program in Israel further demonstrates our focus and commitment to bringing disruptive science-based cannabinoid therapies to Canadian patients, and provide them with innovative cannabis products that have been tested and verified in rigorous clinical studies for the highest level of safety and efficacy.”

Dr. Zohar Koren, Co-founder and CEO of SciCann, stated “we are thrilled and excited to launch this strategic alliance and clinical research collaboration program with Mor Research Applications. Mor has gained substantial experience and proven track record in recent years in the efficient design and execution of large scale clinical studies with cannabinoid-based products for various hard-to-treat diseases such as GVHD (Graft Vs. Host Disease), ulcerative colitis, Crohn’s disease and more. Mor is the perfect strategic partner to enable the execution of a series of proof-of-concept rigorous clinical studies with our line of proprietary indication-specific cannabinoid-based products. We are looking forward eagerly to generating a large pool of much needed clinical data and hard evidence for the potential of cannabinoid-based therapies to treat a wide range of debilitating and hard to treat diseases, results that are much awaited by the global medical and clinical community of researchers in this unique field.”

Warrants Issued

In connection with certain consultant agreements entered into by FSD Pharma, it has issued 2.25 million warrants for class B subordinate voting shares at an exercise price of $0.13 (the “Warrants”). The Warrants expire one year from the date of issuance and include all required statutory hold periods.

About FSD Pharma (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9)

FSD Pharma through its wholly-owned subsidiary FV Pharma, is a licensed producer of marijuana under the Access to Cannabis for Medical Purposes Regulations (ACMPR) having received its cultivation license on October 13, 2017. Headquartered at the former Kraft plant in Cobourg, Ontario, approximately an hour’s drive from Toronto, FV Pharma management’s mission is to transform the facility into the largest hydroponic indoor cannabis facility in the world. FV Pharma intends to target all legal aspects of the cannabis industry, including cultivation, processing, manufacturing, extracts and research and development.

About SciCann Therapeutics

SciCann Therapeutics is a Canadian-Israeli specialty pharmaceutical company, dedicated to the development and commercialization of novel and disruptive pharmaceutical products that target and modulate the endocannabinoid system. SciCann Therapeutics is active in the fields of oncology, pain management, neurodegenerative diseases and inflammatory disorders, and develops a line of proprietary products for the treatment of chosen life-threatening conditions that present a high level of unmet need.

SciCann has created a network of collaborations with leading academic centers and medical institutions in Israel in order to engage in cutting edge science and rigorous clinical studies to develop its products, while using the permissive regulatory climate in Israel for performing its R&D programs quickly and efficiently.

Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Corporation’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the development of the Corporation’s indoor cannabis facility and its business goals and objectives. The forward-looking information contained in this press release is made as of the date hereof, and the Corporation is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward looking-information. The foregoing statements expressly qualify any forward-looking information contained herein.

Neither the Canadian Securities Exchange nor its regulation services provider accept responsibility for the adequacy or accuracy of this release.

Share this:

  • Click to email this to a friend (Opens in new window)
  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Reddit (Opens in new window)
  • Click to share on Telegram (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to share on Pinterest (Opens in new window)
  • Click to share on Tumblr (Opens in new window)
  • Click to share on Pocket (Opens in new window)
Tags: Clalit Healthcare ServicesCSE:HUGEFSD Pharma Inc.Mor Research Applications Ltd.OTC:FSDDFSciCann Therapeutics Inc.

Get Real-Time Updates from MJobserver.com

Unsubscribe
D.M.O. Newswire

D.M.O. Newswire

D.M.O. Newswire is the cannabis industry's trusted news and press release dissemination service.

Related Posts

Cannabis Clinical Trials
Health

Drug Trial Planned For Synthetic Cannabinoid COVID-19 Treatment

June 8, 2020
FSD Pharma Begins Phase 1 In-human Safety and Tolerability Study of Ultra Micro-Palmitolylethanolamide (PEA)
Australia

FSD Pharma Begins Phase 1 In-human Safety and Tolerability Study of Ultra Micro-Palmitolylethanolamide (PEA)

March 9, 2020
Curaleaf Completes Acquisition of Arrow Alternative Care
Investments

FSD Pharma and Solarvest Enhance Commitment to CBD Research Project

February 4, 2020
FSD Pharma to Ring Nasdaq Opening Bell on Wednesday, January 22, 2020
Investments

FSD Pharma to Ring Nasdaq Opening Bell on Wednesday, January 22, 2020

January 17, 2020
What Marijuana Stock Investors Need to Know Before Markets Open
Investments

7 Things Cannabis Investors Should Read Before Markets Open on Thursday, Jan 9, 2020

January 9, 2020
FSD Pharma to Ring Nasdaq Opening Bell on Wednesday, January 22, 2020
Investments

FSD Pharma to Commence Trading on Nasdaq Capital Market Under Symbol ‘HUGE’

January 9, 2020
Load More
Next Post
MJardin Group to Announce Fourth Quarter and Full Year 2018 Financial Results by May 6, 2019

Agritek Holdings, Inc. Delays Filing its Form 10-Q Report

Leave a Comment! Cancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

🚨 Subscribe to Stock Alerts

Get Live Updates on Breaking News

Subscribe Now

βœ‰οΈ Subscribe to Our Newsletter!

* indicates required

πŸ”Ž Search Marijuana Stocks

πŸ“° Recent News

  • J. Arnold Wealth Management Discloses New Stake in Cannabis ETF
  • Bank of America Increases its SNDL Holdings
  • The Lift & Co. Expo is back helping Canada build responsible, prosperous cannabis and psychedelics businesses
  • Bank of America Trims its Stake in Canopy Growth Corp.
  • Ballard Spahr Launches Cannabis Legislation Tracker to ID Industry Trends and Opportunities
Facebook Twitter Instagram LinkedIn Youtube

Cannabis News by Region

  • πŸ‡ΊπŸ‡Έ United States
  • πŸ‡¨πŸ‡¦ Canada
  • πŸ‡¬πŸ‡§ United Kingdom
  • 🌏 Asia
  • 🌍 Europe
  • 🌎 Latin America
  • 🌏 Oceania and Australasia

Cannabis Tools & Resources

  • πŸ“… Calendar
  • πŸ“Š Databases
  • πŸ“‡ Directories
  • πŸ”” RSS Feeds
  • πŸ“Ί Videos

Find Cannabis Business Services

  • βš–οΈ Attorneys & Law Firms
  • πŸ“Š Accountants & Accounting Firms
  • πŸ’‘ Consultants & Consulting Firms
  • πŸ“² Marketing Agencies & Firms

The Daily Marijuana Observer

  • Subscribe
  • About MJobserver.com
  • Affiliate Marketing Disclosure
  • Legal Disclaimer
  • Privacy Policy
  • Contact Us

Advertise with Us

  • πŸ‘€ Advertise
  • πŸ“£ DMO Newswire
  • πŸ“‡ List in Our Databases

Β© 2018 - 2021 D.M.O. Holdings Corp.
DISCLAIMER: DMO Holdings Corp., which owns The Daily Marijuana Observerβ„’ (MJobserver.com), is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. DMO Holdings Corp., which owns MJobserver.com, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. DMO Holdings Corp. or its affiliates, which owns MJobserver.com, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two.

No Result
View All Result
  • Home
  • Latest
  • πŸ”’ PRO
    • πŸ”’ A.M. Watchlist
    • πŸ”’ Analyst Action
  • πŸ’Ό Business
  • πŸ“ˆ Investments
    • πŸ“ˆ Stocks
    • πŸ’° ETFs and Funds
    • πŸ’­ Market Commentary
    • πŸ“° Press Releases
    • πŸ“… Earnings Calendar
  • βš–οΈ Law
    • Laws
    • Politics
    • Intellectual Property
    • Attorneys & Law Firms Database
  • πŸ‘₯ People
    • ⚽ Athletes
    • πŸ’Ό Executives
    • 🌟 Celebrities
    • πŸ›’ Consumers
    • βš•οΈ Doctors
    • πŸ’Š Patients
  • πŸ’Š Health
  • πŸ“‡ Databases
    • πŸ“ˆ Stock Databases
    • πŸ’° Fund Databases
    • πŸ’Ό Service Providers Databases
    • 🏦 Marijuana Stock Brokers
    • πŸ’² Marijuana Cryptocurrencies

Β© 2018 - 2021 D.M.O. Holdings Corp.
DISCLAIMER: DMO Holdings Corp., which owns The Daily Marijuana Observerβ„’ (MJobserver.com), is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. DMO Holdings Corp., which owns MJobserver.com, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. DMO Holdings Corp. or its affiliates, which owns MJobserver.com, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two.

Login to your account below

Forgotten Password? Sign Up

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.